Moderna Therapeutics Overview
- Founded
- 2010
- Status
- Public
- Employees
- 2,700
- Stock Symbol
- MRNA
- Investments
- 3
- Share Price
- $168.26
- (As of Thursday Closing)
Moderna Therapeutics General Information
Description
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020. Moderna had 44 mRNA development programs as of early 2022, with 25 of these in clinical trials. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
Contact Information
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Stock Exchange
NAS
Primary Office
- 200 Technology Square
- Cambridge, MA 02139
- United States
+1 (617) 000-0000
Moderna Therapeutics Timeline
Moderna Therapeutics Stock Performance
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $168.26 | $169.36 | $117.34 - $497.49 | $68.3B | 403M | 8.98M | $30.31 |
Moderna Therapeutics Financials Summary
|
In Thousands, USD |
TTM 31-Dec-2021 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 | FY 2019 31-Dec-2019 |
|---|---|---|---|---|
| EV | 94,653,071 | 94,653,071 | 38,275,827 | 5,493,633 |
| Revenue | 18,471,000 | 18,471,000 | 803,000 | 60,000 |
| EBITDA | 13,517,000 | 13,517,000 | (728,000) | (523,000) |
| Net Income | 12,202,000 | 12,202,000 | (747,000) | (514,000) |
| Total Assets | 24,669,000 | 24,669,000 | 7,337,000 | 1,589,422 |
| Total Debt | 916,000 | 916,000 | 237,000 | 132,364 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Moderna Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
This information is available in the PitchBook Platform. To explore Moderna Therapeutics‘s full profile, request access.
Request a free trialModerna Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
This information is available in the PitchBook Platform. To explore Moderna Therapeutics‘s full profile, request access.
Request a free trialModerna Therapeutics Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The
Drug Discovery
Cambridge, MA
2,700
As of 2021
00.00
00000000000
00.00
0000000
rud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in r
0000000000000
Gaithersburg, MD
0000
As of 0000
00000
000000000
00000
0000000
d exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in rep
0000 000000000
Cambridge, MA
000
As of 0000
00000
00000000
00000
Add Comparison
PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.
Request a free trialModerna Therapeutics Competitors (31)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Novavax | Corporation | Gaithersburg, MD | 0000 | 00000 | 000000000 | 00000 |
| 0000000 0000000000 | Formerly VC-backed | Cambridge, MA | 000 | 00000 | 00000000 | 00000 |
| 0000000 | Formerly VC-backed | Tübingen, Germany | 000 | 00.000 | 00000000 | 00.000 |
| 00000 000000000000 | Corporate Backed or Acquired | Carlsbad, CA | 000 | 0000 | 00000000000 | 0000 |
| 00000000 | Corporation | Austin, TX | 00 | 0000 | 00000000 | 0000 |
Moderna Therapeutics Patents
Moderna Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20210228707-A1 | Coronavirus rna vaccines | Pending | 28-Jan-2020 | 0000000000 | |
| US-20210217484-A1 | Variational autoencoder for biological sequence generation | Pending | 10-Jan-2020 | 000000000 | |
| US-11066355-B2 | Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents | Active | 19-Sep-2019 | 0000000000 | 000 |
| US-20210087135-A1 | Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents | Granted | 19-Sep-2019 | 0000000000 | |
| CA-3139321-A1 | Polynucleotides for disrupting immune cell activity and methods of use thereof | Pending | 07-May-2019 | C12N15/62 |
Moderna Therapeutics Executive Team (46)
Moderna Therapeutics Board Members (19)
| Name | Representing | Role | Since |
|---|---|---|---|
| Elizabeth Nabel MD | Self | Board Member | 000 0000 |
| Elizabeth Tallett | Moderna Therapeutics | Board Member | 000 0000 |
| Israel Ruiz | Moderna Therapeutics | Board Member | 000 0000 |
| Noubar Afeyan Ph.D | Self | Chairman & Board Member | 000 0000 |
| Paul Sagan | Self | Board Member | 000 0000 |
Moderna Therapeutics Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %ile
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trialModerna Therapeutics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
This information is available in the PitchBook Platform. To explore Moderna Therapeutics‘s full profile, request access.
Request a free trialModerna Therapeutics Investments (3)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 000000 | 22-Oct-2015 | 000000000 | 0000 | Therapeutic Devices | |
| 0000000000 | 01-Jan-2015 | 000000000 | 00000 | Biotechnology | |
| Onkaido | 14-Jan-2014 | Corporate | 0000 | Drug Discovery |
Moderna Therapeutics Subsidiaries (2)
| Company Name | Industry | Location | Founded |
|---|---|---|---|
| Valera | Therapeutic Devices | Cambridge, MA | 2015 |
| 0000000 | Drug Discovery | Cambridge, MA | 0000 |
Moderna Therapeutics Exits (2)
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| 000000 | 22-Oct-2015 | 000000000 | 0000 | Completed |
|
| Onkaido | 14-Jan-2014 | Corporate | 0000 | Completed |